Last updated: May 25, 2026
Suppliers for Saxagliptin and Metformin Hydrochloride (APIs, Intermediates, and Finished-Dose Contract Manufacturing)
Saxagliptin and metformin hydrochloride are widely sourced from multiple global API and intermediate suppliers, with final combination tablets typically produced by CDMOs under development-stage to commercial supply chains. The supplier landscape is dominated by established API manufacturers for saxagliptin (including key China-based producers) and by large-scale metformin API and salt makers. For contract manufacturing of the fixed-dose combination, sourcing is usually bid on the basis of API qualification status, DMF/CEP alignment, tablet/compression capability, and stability data for the specific strength (commonly saxagliptin 5 mg plus metformin in immediate-release strengths).
Which companies supply saxagliptin API and key intermediates?
Saxagliptin API supply is concentrated in manufacturers that can support cGMP API production plus a supply chain for core diketopiperazine-like scaffolds and related amide/linker steps used in the synthetic route. In practice, customers qualify suppliers by DMF readiness (or EDQM CEP equivalence) and by their ability to provide detailed impurity and residual solvent profiles for the specific grade (often “pharmaceutical” or “USP/EP” equivalents).
Common saxagliptin API supplier profiles
- Full API producers with internal intermediate capability (more stable impurity control).
- API producers that buy select intermediates but provide full lot traceability and impurity “walkdown” packages for registration.
- Suppliers able to support both commercial and regulatory filings (DMF, CEP/EDQM, and change notification history).
What intermediates are typically sourced for saxagliptin?
Saxagliptin manufacturing routes use multiple chiral/functional-group intermediates. For procurement planning, upstream intermediates are generally sourced under qualification like:
- Nitrogen heterocycle intermediates
- Protected amine and carboxamide-linked fragments
- Oxidation/reduction intermediates and salt-forming agents
- Final purification intermediates tied to impurity control
Which companies supply metformin hydrochloride API and salts?
Metformin hydrochloride is one of the most globally produced APIs because the chemistry is mature and scale-friendly. Supply is typically broad across:
- Metformin base producers that then convert to metformin hydrochloride salt
- Direct metformin hydrochloride API producers
- Large integrated producers with solvent and purification infrastructure
Metformin supply chain characteristics that drive supplier selection
- Consistent impurity profile (including related substances and nitrosamine controls where applicable)
- Batch reproducibility for crystallization and polymorph control
- Capability for both immediate-release and extended-release grades (where needed)
- Ability to support DMF updates and supply continuity during change management
Who manufactures saxagliptin and metformin combination tablets (CDMO/finished-dose)?
Fixed-dose combination tablets are generally produced by CDMOs or by vertically integrated generic brand manufacturers. Supplier selection hinges on:
- Tablet compression line capability (blend uniformity for low-dose saxagliptin plus higher-dose metformin)
- Film-coating capability (if applicable to the marketed product form)
- Stability program alignment (ICH conditions and long-term monitoring)
- Analytical method transfer experience (assays for saxagliptin, metformin, and specified impurities)
Formulation and process considerations affecting CDMO fit
- Low-dose saxagliptin requires tighter content uniformity and segregation control during blending and dosing.
- Metformin requires robust dissolution and impurity controls, including protection against hygroscopic effects.
- Packaging qualification is critical because metformin formulations can be sensitive to moisture; suppliers must demonstrate robust container-closure compatibility.
How does supplier availability differ by market (US, EU, emerging markets)?
Supplier qualification differs by regulatory regime:
- US (FDA): API qualification is tied to DMF/ASMF submissions, cGMP compliance, and ANDA bridging data for finished-dose entry. Supplier changes trigger supplement requirements and can slow approval timelines.
- EU (EMA/EDQM): CEP/ASMF and compliance with EU GMP and impurity specifications drive selection.
- Emerging markets: often rely on simpler documentation packages and local regulatory pathways, but quality expectations increasingly mirror EU/US standards.
From a business-risk view, the most reliable supply chains are those where:
- The API manufacturer supports DMF changes quickly
- The finished-dose CDMO has a history producing the exact strength or a directly comparable composition
- Analytical method capability covers saxagliptin-specific impurities and polymorph-related dissolution behavior
What supplier qualification documentation is used for saxagliptin + metformin combination?
Qualification typically uses:
- API DMF (or ASMF) crosswalk to the drug substance in the finished product submission
- CoA templates with impurity ranges and residual solvent declarations
- Drug product process validation package for blend, compression, and coating steps
- Stability data for the specific strength and packaging configuration
- Change control system review (CAPA history, deviation reporting, and batch-to-batch consistency)
What generic entry risks exist for saxagliptin/metformin combinations that affect sourcing?
Supplier and qualification risk often determines whether a generic or authorized-licensed product can launch on time. Key risks:
- Inconsistent API impurity profiles between suppliers
- Delays in DMF readiness or DMF letter approvals
- Finished-dose dissolution failures tied to blend properties and metformin salt behavior
- Stability failures in moisture/heat stressing, driven by excipient selection or packaging mismatch
These risks affect:
- Contract award timing for CDMOs
- Batch timelines for clinical and commercial supply
- Ability to support regulatory amendments quickly
Supplier landscape comparisons: saxagliptin vs metformin (what to prioritize)
Procurement priorities typically differ:
Saxagliptin procurement priorities
- Impurity specification discipline for low-dose accuracy
- Synthetic route consistency to avoid impurity drift
- Ability to deliver regulatory-ready documentation for filings
Metformin procurement priorities
- Crystallization consistency and salt conversion control (metformin hydrochloride)
- Polymorph and hydrate behavior where relevant to dissolution
- Scale pricing and continuity risk management
Key Takeaways
- Saxagliptin API supply is more qualification-sensitive because low-dose performance depends on impurity control and regulatory-ready documentation.
- Metformin hydrochloride API supply is broader and generally easier to source, but salt form and impurity consistency still drive product performance.
- Finished-dose combination tablets require CDMO capability in tight content uniformity blending and moisture-stable tablet packaging.
- Generic or authorized entry speed is mostly determined by API qualification readiness (DMF/ASMF) and tablet process validation reproducibility rather than API availability alone.
FAQs
- What is the most common production route supplier documentation package for saxagliptin API?
- Which analytical tests are critical when switching metformin hydrochloride API suppliers for a fixed-dose combination?
- How do DMF readiness delays affect contract manufacturing timelines for saxagliptin/metformin tablets?
- What packaging choices most often mitigate moisture-related stability risks in metformin-containing tablet products?
- How does impurity drift in saxagliptin impact blend uniformity and finished-dose dissolution outcomes?
References
- FDA. (n.d.). Drug Master Files (DMF). U.S. Food and Drug Administration. https://www.fda.gov/
- EMA. (n.d.). ASMF and CEP information for medicines. European Medicines Agency. https://www.ema.europa.eu/
